- Home
- PRME
PRME
Prime Medicine Inc.
as 11-08-2024 2:39pm EST
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Upcoming Earnings Alert:
Get ready for potential market movements as Prime Medicine Inc. PRME prepares to release earnings report on 12 Nov 2024.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 424.9M | IPO Year: | 2022 |
| Target Price: | $14.14 | AVG Volume (30 days): | 964.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.28 - $9.86 | Next Earning Date: | 11-12-2024 |
| Revenue: | $591,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -10.17% |
Latest Prime Medicine Inc. News
PRME Breaking Stock News: Dive into PRME Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Prime Medicine to Participate in Upcoming Investor Conferences
Motley Fool
11 days ago
12 High-Growth Stocks That Could Deliver Parabolic Returns
GlobeNewswire
15 days ago
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
Motley Fool
23 days ago
Why I Keep Buying These 14 Incredible Growth Stocks
GlobeNewswire
24 days ago
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
Zacks
a month ago
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
Pharmaceutical Technology
a month ago
BMS and Prime ink potential $3.5bn deal to develop T cell therapies
Motley Fool
a month ago
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
Compare PRME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRME Prime Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.